These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28193277)

  • 1. Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells.
    Meng P; Dong QC; Tan GG; Wen WH; Wang H; Zhang G; Wang YZ; Jing YM; Wang C; Qin WJ; Yuan JL
    BMC Urol; 2017 Feb; 17(1):14. PubMed ID: 28193277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
    Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
    Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
    Zhao W; Xu Y; Kong D; Liu R; Zhang Z; Jin C; Zhang Z; Xiu Y
    Urol Oncol; 2009; 27(5):539-47. PubMed ID: 18639471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody.
    Ikegami S; Yamakami K; Ono T; Sato M; Suzuki S; Yoshimura I; Asano T; Hayakawa M; Tadakuma T
    Hum Gene Ther; 2006 Oct; 17(10):997-1005. PubMed ID: 17032155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
    Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
    J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
    Zhao FJ; Zhang S; Yu ZM; Xia SJ; Li H
    Prostate Cancer Prostatic Dis; 2009; 12(2):166-71. PubMed ID: 18626508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
    Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
    J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
    Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
    Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
    Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The construction of recombinant plasmid with prostate-specific membrane antigen promoter controlling reporter gene expression].
    Zeng H; Li H; Liao YC; Li X; Wu Q; Yang YR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):169-71. PubMed ID: 15807257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
    Liu R; Sun J; Zhang Z; Xu Y
    Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.
    Coulter JA; Page NL; Worthington J; Robson T; Hirst DG; McCarthy HO
    J Gene Med; 2010 Sep; 12(9):755-65. PubMed ID: 20821746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer.
    Hattori Y; Maitani Y
    Cancer Sci; 2006 Aug; 97(8):787-98. PubMed ID: 16800821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.